BRD2 and neoplasm: We used a tumor-informed, personalized assay to detect ctDNA in blood collected at 4 time points: at pretreatment (T0), 3 weeks after initiation of paclitaxel treatment with or without investigational agents (T1), 12 weeks between paclitaxel-based and anthracycline treatment (T2), and after NAT (T3).